In Silico Design and Experimental Validation of Combination Therapy for Pancreatic Cancer

IEEE/ACM Trans Comput Biol Bioinform. 2020 May-Jun;17(3):1010-1018. doi: 10.1109/TCBB.2018.2872573. Epub 2018 Sep 28.

Abstract

The number of deaths associated with Pancreatic Cancer has been on the rise in the United States making it an especially dreaded disease. The overall prognosis for pancreatic cancer patients continues to be grim because of the complexity of the disease at the molecular level involving the potential activation/inactivation of several diverse signaling pathways. In this paper, we first model the aberrant signaling in pancreatic cancer using a multi-fault Boolean Network. Thereafter, we theoretically evaluate the efficacy of different drug combinations by simulating this boolean network with drugs at the relevant intervention points and arrive at the most effective drug(s) to achieve cell death. The simulation results indicate that drug combinations containing Cryptotanshinone, a traditional Chinese herb derivative, result in considerably enhanced cell death. These in silico results are validated using wet lab experiments we carried out on Human Pancreatic Cancer (HPAC) cell lines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Algorithms
  • Antineoplastic Agents / pharmacology
  • Cell Line, Tumor
  • Computational Biology / methods*
  • Computer Simulation*
  • Drug Therapy, Combination
  • Humans
  • Pancreatic Neoplasms*
  • Phenanthrenes / pharmacology*
  • Signal Transduction* / drug effects
  • Signal Transduction* / genetics

Substances

  • Antineoplastic Agents
  • Phenanthrenes
  • cryptotanshinone